Immunovia AB (publ) (STO:IMMNOV)
Sweden · Delayed Price · Currency is SEK 0.1296
-0.0022 (-1.67%)
Sep 4, 2026, 5:29 PM CET
Immunovia AB Income Statement
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 1.21 | 0.69 | 0.93 | 1.58 | 1.15 | 0.84 |
| 1.21 | 0.69 | 0.93 | 1.58 | 1.15 | 0.84 | |
Revenue Growth | 31.77% | -26.42% | -40.89% | 37.55% | 35.66% | 133.15% |
Cost of Revenue | 0.52 | 0.14 | - | 6.68 | 4.21 | -14.97 |
Gross Profit | 0.69 | 0.55 | 0.93 | -5.11 | -3.07 | 15.81 |
Selling, General & Admin | 80.8 | 77.73 | 94.48 | 148.3 | 162.97 | 162.09 |
Other Operating Expenses | 0.83 | 0.95 | 3.21 | 1.56 | 0.26 | 1.4 |
Operating Expenses | 83.5 | 81 | 111.11 | 291.58 | 188.14 | 182.55 |
Operating Income | -82.81 | -80.45 | -110.17 | -296.69 | -191.21 | -166.74 |
Interest Expense | - | -2.04 | -1.86 | -1.17 | -1.6 | -1.43 |
Interest & Investment Income | 58.43 | 0.54 | 34.73 | 6.28 | 0.75 | 0.71 |
Currency Exchange Gain (Loss) | -63.96 | -63.96 | 0.76 | -17.87 | 23.97 | 11.5 |
Other Non Operating Income (Expenses) | 0.01 | - | - | 0.01 | - | - |
EBT Excluding Unusual Items | -88.34 | -145.92 | -76.54 | -309.44 | -168.09 | -155.97 |
Pretax Income | -88.34 | -145.92 | -76.54 | -309.44 | -168.09 | -155.97 |
Net Income | -88.34 | -145.92 | -76.54 | -309.44 | -168.09 | -155.97 |
Net Income to Common | -88.34 | -145.92 | -76.54 | -309.44 | -168.09 | -155.97 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 546 | 344 | 83 | 39 | 23 | 23 |
Shares Outstanding (Diluted) | 546 | 344 | 83 | 39 | 23 | 23 |
Shares Change | 180.08% | 316.79% | 112.20% | 72.02% | - | 6.05% |
EPS (Basic) | -0.16 | -0.42 | -0.93 | -7.95 | -7.43 | -6.89 |
EPS (Diluted) | -0.16 | -0.42 | -0.93 | -7.95 | -7.43 | -6.89 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -77.35 | -78.4 | -96.75 | -147.06 | -176.84 | -155.75 |
Free Cash Flow Per Share | -0.14 | -0.23 | -1.17 | -3.78 | -7.81 | -6.88 |
Gross Margin | 56.98% | 80.15% | 100.00% | - | -267.77% | 1873.58% |
Operating Margin | -6838.40% | -11744.82% | -11833.94% | -18837.27% | -16699.48% | -19756.04% |
Profit Margin | -7294.39% | -21301.46% | -8221.38% | -19646.92% | -14680.52% | -18479.38% |
Free Cash Flow Margin | -6387.37% | -11445.26% | -10392.37% | -9336.95% | -15444.37% | -18453.67% |
EBITDA | -83.22 | -80.41 | -108.43 | -167.63 | -185.15 | -161.1 |
D&A For EBITDA | -0.41 | 0.04 | 1.75 | 129.05 | 6.06 | 5.64 |
EBIT | -82.81 | -80.45 | -110.17 | -296.69 | -191.21 | -166.74 |
Revenue as Reported | 1.29 | 0.75 | 1.69 | 1.8 | 1.2 | 0.96 |